Name (Synonyms) | Correlation | |
---|---|---|
drug2739 | anti-SARS-CoV-2 convalescent plasma Wiki | 0.50 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
Description: Progression to mechanical ventilation or death within the first 14 days of enrollment.
Measure: Mechanical Ventilation or Death Endpoint Time: Day 14Description: Progression to mechanical ventilation or death within the first 28 days of enrollment.
Measure: Mechanical Ventilation or Death Endpoint Time: Day 28Description: Clinical efficacy of CCP relative to the control arm in adults hospitalized with COVID-19 according to clinical status as assessed by 8-point ordinal scale. Death; Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities.
Measure: 8-Point Ordinal Scale Endpoint Time: Day 29